of (South). RATIONALE: Post-infectious bronchiolitis obliterans (PIBO) is an irreversible form of chronic obstructive lung disease secondary to severe lower respiratory infection (LRI). The children who had PIBO during infancy usually show recurrent wheezing and frequent exacerbations due to respiratory infection. We followed them and examined their clinical characteristics, airway hyperresponsiveness, and lung function parameters. METHODS: Forty-one patients diagnosed with PIBO before 3 years of age were enrolled. Diagnosis of PIBO was made according to the previously described criteria: 1) history of acute LRI in previously healthy children 2) unresolved respiratory symptoms associated with airway obstruction (cough, shortness of breath on exertion and/or abnormal breath sounds) that last for more than 6 weeks after the initial episode despite treatment 3) mosaic perfusion with air trapping, bronchiectasis, or atelectasis on pulmonary HRCT. Spirometry and methacholine challenge test were performed in these children at 6 years of age and lung function parameters were compared with age-matched control values using Z score. RESULTS: Mean onset age of PIBO was 21.8 months. Mean follow-up period was 61.1 months. PIBO patients showed significantly lower FEV 1 and FEF 25-75% Z scores compared with age-matched control values. Bronchial hyperresponsiveness was observed in more than 40% of PIBO patients and it was not related with the atopic status of the patients. CONCLUSIONS: In our study, the children who had PIBO during infancy had reduced lung function parameters and many of them showed bronchial hyperresponsiveness. Our study suggests that PIBO during early infancy might cause persistent lung function impairment. Johns Hopkins University, Baltimore, MD. RATIONALE: Chronic lower airway respiratory conditions in children are a diagnostic challenge as common conditions like asthma, as well as other respiratory, anatomical, genetic, infectious, immunological and systemic diseases may have a similar presentation. Bronchoscopy with bronchoalveolar lavage (FBC+BAL) is a diagnostic aid, especially in those patients with poor response to treatment. Accordingly, in our study, we used FBC+BAL to characterize underlying lung abnormalities in children with lower airway symptoms unresponsive to conventional treatments. METHODS: We conducted a retrospective case review of 45 children who underwent FBC+BAL due to unresponsive lower respiratory airway symptoms during 2017 in a tertiary pediatric center in Colombia. RESULTS: Patients were aged 4-179 months (median age 36.5 months) and there was no sex predominance (24 males). Initial diagnosis included asthma (46.7%), recurrent wheezing (33.3%) and chronic cough (17.8%). Common imaging findings prior to FBC+BAL included consolidations (44.2%), atelectasis (42%), mosaic attenuation (21%). Bronchoscopy findings included: airway anatomical abnormalities (n 5 3), tuberculosis (n 5 2), BAL lipophagous index >86 suggesting chronic aspiration (n 5 14), positive BAL culture for common bacteria (n 5 9) and atypical microorganisms (Cytomegalovirus 5 11, candida dublinensis 5 1) in 12 patients. CONCLUSIONS: Pulmonary infections by mycobacteria and atypical microorganisms, anatomical abnormalities and chronic aspiration underlay wheezing and lower airway respiratory symptoms in 68% of patients in our study. Bronchoscopy proved definitive for the appropriate diagnosis and treatment of these conditions. Early recognition of cases in need for bronchoscopic evaluation of the airway is required for all physicians treating children with lower airway respiratory symptoms. At the molecular level, hyperoxic exposure causes an increase in reactive oxygen species, leading to an accumulation of 4-Hydroxy-2-nonenal (4HNE), a lipid peroxidation product causes protein adducts and inhibits the activity of the mitochondrial enzyme Aldh2 (Aldehyde dehydrogenase), which is involved in metabolism of alcohol. Currently, it is wellknown that the use of compound Alda-1 enhances Aldh2 activity. Therefore, use of Alda-1 may reduce the effect of acute lung injury. METHODS: DMSO or Alda-1 (20 mM), then they were exposed to 100% oxygen 48 hours. The lung samples, as well as Bronchial Alveolar Lavage Fluid, were collected for the evaluation of infiltration of cytokines, inflammation, autophagy, and apoptosis by Diff Kwik staining, H&E staining, and western blot. RESULTS: The Mice treated with DMSO in hyperoxia showed more cytokine and neutrophil infiltration and elevated inflammation than mice treated with Alda-1 in hyperoxia. The western blot analysis of Alda-1-treated mice showed reduced cytochrome C release, reduced LC3B, and reduced NF-kB-p65, while also showing a decrease in oxidative stress, inflammation and autophagy. CONCLUSIONS: The findings imply that Alda-1, an Aldh2 activator is a potential therapeutic drug for the treatment of acute lung injury.
Johns Hopkins University, Baltimore, MD. RATIONALE: Chronic lower airway respiratory conditions in children are a diagnostic challenge as common conditions like asthma, as well as other respiratory, anatomical, genetic, infectious, immunological and systemic diseases may have a similar presentation. Bronchoscopy with bronchoalveolar lavage (FBC+BAL) is a diagnostic aid, especially in those patients with poor response to treatment. Accordingly, in our study, we used FBC+BAL to characterize underlying lung abnormalities in children with lower airway symptoms unresponsive to conventional treatments. METHODS: We conducted a retrospective case review of 45 children who underwent FBC+BAL due to unresponsive lower respiratory airway symptoms during 2017 in a tertiary pediatric center in Colombia. RESULTS: Patients were aged 4-179 months (median age 36.5 months) and there was no sex predominance (24 males). Initial diagnosis included asthma (46.7%), recurrent wheezing (33.3%) and chronic cough (17.8%). Common imaging findings prior to FBC+BAL included consolidations (44.2%), atelectasis (42%), mosaic attenuation (21%). Bronchoscopy findings included: airway anatomical abnormalities (n 5 3), tuberculosis (n 5 2), BAL lipophagous index >86 suggesting chronic aspiration (n 5 14), positive BAL culture for common bacteria (n 5 9) and atypical microorganisms (Cytomegalovirus 5 11, candida dublinensis 5 1) in 12 patients. CONCLUSIONS: Pulmonary infections by mycobacteria and atypical microorganisms, anatomical abnormalities and chronic aspiration underlay wheezing and lower airway respiratory symptoms in 68% of patients in our study. Bronchoscopy proved definitive for the appropriate diagnosis and treatment of these conditions. Early recognition of cases in need for bronchoscopic evaluation of the airway is required for all physicians treating children with lower airway respiratory symptoms. RATIONALE: Acute lung injury (ALI) is a critical lung disorder where the inefficient oxygen uptake causes acute hypoxemia and Acute Respiratory Distress Syndrome (ARDS). There are nearly 200,000 annual cases of ALI in the United States alone, and the incidence rate is increasing. At the molecular level, hyperoxic exposure causes an increase in reactive oxygen species, leading to an accumulation of 4-Hydroxy-2-nonenal (4HNE), a lipid peroxidation product causes protein adducts and inhibits the activity of the mitochondrial enzyme Aldh2 (Aldehyde dehydrogenase), which is involved in metabolism of alcohol. Currently, it is wellknown that the use of compound Alda-1 enhances Aldh2 activity. Therefore, use of Alda-1 may reduce the effect of acute lung injury. METHODS: DMSO or Alda-1 (20 mM), then they were exposed to 100% oxygen 48 hours. The lung samples, as well as Bronchial Alveolar Lavage Fluid, were collected for the evaluation of infiltration of cytokines, inflammation, autophagy, and apoptosis by Diff Kwik staining, H&E staining, and western blot. RESULTS: The Mice treated with DMSO in hyperoxia showed more cytokine and neutrophil infiltration and elevated inflammation than mice treated with Alda-1 in hyperoxia. The western blot analysis of Alda-1-treated mice showed reduced cytochrome C release, reduced LC3B, and reduced NF-kB-p65, while also showing a decrease in oxidative stress, inflammation and autophagy. CONCLUSIONS: The findings imply that Alda-1, an Aldh2 activator is a potential therapeutic drug for the treatment of acute lung injury.
